Biopharmaceutical company GSK (LSE/NYSE: GSK) on Wednesday declared promising EAGLE-1 phase III trial results for gepotidacin, a potential breakthrough oral antibiotic targeting uncomplicated urogenital gonorrhoea (GC).

The trial data, to be presented at ESCMID Global on 30 April 2024, showcases gepotidacin's 92.6% microbiological success rate, positioning it as a viable treatment amidst rising resistance concerns.

EAGLE-1 demonstrates gepotidacin's non-inferiority compared to the leading combination therapy, intramuscular ceftriaxone plus oral azithromycin, essential in addressing GC's global burden with an estimated 82 million new cases annually. The safety profile aligns with earlier trials, with predominantly mild to moderate gastrointestinal adverse events.

GSK's infectious diseases portfolio advances with gepotidacin's potential, supported by the completion of the EAGLE phase III programme. Moreover, GSK's commitment to combating antimicrobial resistance is underscored by partnerships and licensing agreements, strengthening its position in the fight against infectious diseases.